3 February 2012 - US Idenix Pharmaceuticals Inc (NASDAQ:IDIX) said today that the FDA has lifted the partial clinical hold on IDX184 and that its 12-week Phase IIb trial assessing IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV) may continue.

IDX184, the firm'...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up